Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway
Open Access
- 29 February 2024
- journal article
- research article
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 39 (1) , 98-108
Abstract
Background: Sodium-dependent glucose cotransporter 2 (SGLT2) mediates glucose reabsorption in the renal proximal tubules, and SGLT2 inhibitors are used as therapeutic agents for treating type 2 diabetes mellitus. This study aimed to elucidate the effects and mechanisms of SGLT2 inhibition on hepatic glucose metabolism in both serum deprivation and serum supplementation states.Methods: Huh7 cells were treated with the SGLT2 inhibitors empagliflozin and dapagliflozin to examine the effect of SGLT2 on hepatic glucose uptake. To examine the modulation of glucose metabolism by SGLT2 inhibition under serum deprivation and serum supplementation conditions, HepG2 cells were transfected with SGLT2 small interfering RNA (siRNA), cultured in serum-free Dulbecco’s modified Eagle’s medium for 16 hours, and then cultured in media supplemented with or without 10% fetal bovine serum for 8 hours.Results: SGLT2 inhibitors dose-dependently decreased hepatic glucose uptake. Serum deprivation increased the expression levels of the gluconeogenesis genes peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), glucose 6-phosphatase (G6pase), and phosphoenolpyruvate carboxykinase (PEPCK), and their expression levels during serum deprivation were further increased in cells transfected with SGLT2 siRNA. SGLT2 inhibition by siRNA during serum deprivation induces nuclear localization of the transcription factor forkhead box class O 1 (FOXO1), decreases nuclear phosphorylated-AKT (p-AKT), and p-FOXO1 protein expression, and increases phosphorylated-adenosine monophosphate-activated protein kinase (p-AMPK) protein expression. However, treatment with the AMPK inhibitor, compound C, reversed the reduction in the protein expression levels of nuclear p- AKT and p-FOXO1 and decreased the protein expression levels of p-AMPK and PEPCK in cells transfected with SGLT2 siRNA during serum deprivation.Conclusion: These data show that SGLT2 mediates glucose uptake in hepatocytes and that SGLT2 inhibition during serum deprivation increases gluconeogenesis via the AMPK/AKT/FOXO1 signaling pathway.Keywords
Funding Information
- National Research Foundation of Korea (2022R1F1A1072882)
This publication has 41 references indexed in Scilit:
- Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and diseasePflügers Archiv - European Journal of Physiology, 2020
- A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 CellsNatural Products and Bioprospecting, 2018
- FOXO transcription factors at the interface of metabolism and cancerInternational Journal of Cancer, 2017
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 2015
- Energy Metabolism in the Liver2014
- FoxO1, the transcriptional chief of staff of energy metabolismBone, 2012
- FoxO transcription factors; Regulation by AKT and 14-3-3 proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interactionNature, 2003
- MAPK signal pathways in the regulation of cell proliferation in mammalian cellsCell Research, 2002